Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bioeffective A** is a proprietary, multi-constituent conifer green needle extract developed by Solagran, now Prenolica. Also called **Conifer Green Needle Complex**, it is produced from green conifer needles through a proprietary extraction process and contains a broad mixture of naturally occurring constituents, including chlorophyll-related compounds, carotenoids, polyprenols, phytosterols, fatty acids, resin acids, vitamins, and minerals. It is marketed primarily as an oral antioxidant and general-wellbeing complementary medicine/nutraceutical, with topical formulations also marketed for skin and wound-support applications. Its activity is not attributable to a single defined molecular target; reported biological effects include antioxidant, antibacterial, antifungal, and tissue-repair-related activity. A published observational pilot study evaluated Conifer Green Needle Complex in patients with precancerous gastric lesions, but Bioeffective A is not an INN-designated pharmaceutical drug or a conventional target-defined therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bioeffective A.